• Home
  • AMD

Age-related Macular Degeneration (AMD)

A debilitating burden on patients and healthcare providers

> 4.2 Mn

patients need antibody drugs

6–12

eye injections
per year

1 Mn

non-responsive
patients

AMD causes vision loss that progressively gets worse with age.

Patients face difficulties with day-to-day tasks and are at high risk of social isolation and depression.

Therapeutic Challenges in AMD

Elderly patients suffering from Age-Related Macular Degeneration have to travel monthly to get an eye injection from their medical care provider. Moreover, many patients do not respond to the treatment. An aging global population further compounds this problem.

EyeStrongTM

Reducing the Burden of
Age Related Macular Degeneration

EyeStrongTM

  • A proprietary novel drug for wet AMD
  • Minimally invasive
  • Higher efficacy with higher antibody concentration
  • Ease of delivery - Sustained-release formulation

ProteostrongTM
Technology

EyeStrongTM, Lamark’s proprietary novel biologic for Wet AMD, with promising efficacy in preclinical & ex-vivo models

  • Targets a novel pathway
  • High potency solution for neoangiogenesis

Our Impact

Significant reduction in injection frequency
Higher efficacy leading to better patient outcomes
Lower treatment cost reduces the burden on the healthcare system

Our Pipeline

Transforming the outlook for AMD

Novel formulations that protect vision and empower independence.
Interested in partnering with us? We’d love to connect. Reach out today!
Write to Us